Report Detail

This report covers market size and forecasts of Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs, including the following market information:
Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Size by Company, 2019- 2020 (quarterly data), (US$ Million) & (K Units)

Key market players
Major competitors identified in this market include GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck & Co, Tesaro, Acacia Pharma, Aphios, Barr Laboratories, Baxter Healthcare, Eisai, Especificos Stendhal, F.Hoffmann La Roche, Mundipharma, Mylan Pharmaceuticals, OPKO Health, Orchid Healthcare, etc.

Based on the Region:
Asia-Pacific (China, Japan, South Korea, India and ASEAN)
North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)

Based on the Type:
Aloxi (palonosetron)
Kytril Generic (granisetron)
Emend (aprepitant)
Akynzeo (netupitant-palonosetron)

Based on the Application:
Blood Cancer
Breast Cancer
Gastrointestinal Tract Cancer
Others


  • 1.1 Research Scope
  • 1.2 Market Segmentation
  • 1.3 Research Objectives
  • 1.4 Research Methodology
    • 1.4.1 Research Process
    • 1.4.2 Data Triangulation
    • 1.4.3 Research Approach
    • 1.4.4 Base Year
  • 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
    • 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.5.2 Covid-19 Impact: Commodity Prices Indices
    • 1.5.3 Covid-19 Impact: Global Major Government Policy
  • 1.6 The Covid-19 Impact on Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Industry
  • 1.7 COVID-19 Impact: Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Trends
  • 2 Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Market Size Analysis

    • 2.1 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Business Impact Assessment - COVID-19
      • 2.1.1 Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
      • 2.1.2 Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
    • 2.2 Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Market Size 2020-2021
    • 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
      • 2.3.1 Drivers
      • 2.3.2 Restraints
      • 2.3.3 Opportunities
      • 2.3.4 Challenges

    3 Quarterly Competitive Assessment, 2020

    • 3.1 Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Market Size by Manufacturers, 2019 VS 2020
    • 3.2 Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Factory Price by Manufacturers
    • 3.3 Location of Key Manufacturers Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Manufacturing Factories and Area Served
    • 3.4 Date of Key Manufacturers Enter into Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market
    • 3.5 Key Manufacturers Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Offered
    • 3.6 Mergers & Acquisitions, Expansion Plans

    4 Impact of Covid-19 on Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Segments, By Type

    • 4.1 Introduction
      • 1.4.1 Aloxi (palonosetron)
      • 1.4.2 Kytril Generic (granisetron)
      • 1.4.3 Emend (aprepitant)
      • 1.4.4 Akynzeo (netupitant-palonosetron)
    • 4.2 By Type, Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Size, 2019-2021
      • 4.2.1 By Type, Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Size by Type, 2020-2021
      • 4.2.2 By Type, Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Price, 2020-2021

    5 Impact of Covid-19 on Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Segments, By Application

    • 5.1 Overview
      • 5.5.1 Blood Cancer
      • 5.5.2 Breast Cancer
      • 5.5.3 Gastrointestinal Tract Cancer
      • 5.5.4 Others
    • 5.2 By Application, Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Size, 2019-2021
      • 5.2.1 By Application, Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Size by Application, 2019-2021
      • 5.2.2 By Application, Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Price, 2020-2021

    6 Geographic Analysis

    • 6.1 Introduction
    • 6.2 North America
      • 6.2.1 Macroeconomic Indicators of US
      • 6.2.2 US
      • 6.2.3 Canada
    • 6.3 Europe
      • 6.3.1 Macroeconomic Indicators of Europe
      • 6.3.2 Germany
      • 6.3.3 France
      • 6.3.4 UK
      • 6.3.5 Italy
    • 6.4 Asia-Pacific
      • 6.4.1 Macroeconomic Indicators of Asia-Pacific
      • 6.4.2 China
      • 6.4.3 Japan
      • 6.4.4 South Korea
      • 6.4.5 India
      • 6.4.6 ASEAN
    • 6.5 Rest of World
      • 6.5.1 Latin America
      • 6.5.2 Middle East and Africa

    7 Company Profiles

    • 7.1 GlaxoSmithKline
      • 7.1.1 GlaxoSmithKline Business Overview
      • 7.1.2 GlaxoSmithKline Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Production and Revenue, 2020
      • 7.1.3 GlaxoSmithKline Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Introduction
      • 7.1.4 GlaxoSmithKline Response to COVID-19 and Related Developments
    • 7.2 Helsinn
      • 7.2.1 Helsinn Business Overview
      • 7.2.2 Helsinn Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Production and Revenue, 2020
      • 7.2.3 Helsinn Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Introduction
      • 7.2.4 Helsinn Response to COVID-19 and Related Developments
    • 7.3 Heron Therapeutics
      • 7.3.1 Heron Therapeutics Business Overview
      • 7.3.2 Heron Therapeutics Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Production and Revenue, 2020
      • 7.3.3 Heron Therapeutics Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Introduction
      • 7.3.4 Heron Therapeutics Response to COVID-19 and Related Developments
    • 7.4 Merck & Co
      • 7.4.1 Merck & Co Business Overview
      • 7.4.2 Merck & Co Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Production and Revenue, 2020
      • 7.4.3 Merck & Co Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Introduction
      • 7.4.4 Merck & Co Response to COVID-19 and Related Developments
    • 7.5 Tesaro
      • 7.5.1 Tesaro Business Overview
      • 7.5.2 Tesaro Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Production and Revenue, 2020
      • 7.5.3 Tesaro Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Introduction
      • 7.5.4 Tesaro Response to COVID-19 and Related Developments
    • 7.6 Acacia Pharma
      • 7.6.1 Acacia Pharma Business Overview
      • 7.6.2 Acacia Pharma Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Production and Revenue, 2020
      • 7.6.3 Acacia Pharma Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Introduction
      • 7.6.4 Acacia Pharma Response to COVID-19 and Related Developments
    • 7.7 Aphios
      • 7.7.1 Aphios Business Overview
      • 7.7.2 Aphios Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Production and Revenue, 2020
      • 7.7.3 Aphios Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Introduction
      • 7.7.4 Aphios Response to COVID-19 and Related Developments
    • 7.8 Barr Laboratories
      • 7.8.1 Barr Laboratories Business Overview
      • 7.8.2 Barr Laboratories Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Production and Revenue, 2020
      • 7.8.3 Barr Laboratories Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Introduction
      • 7.8.4 Barr Laboratories Response to COVID-19 and Related Developments
    • 7.9 Baxter Healthcare
      • 7.9.1 Baxter Healthcare Business Overview
      • 7.9.2 Baxter Healthcare Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Production and Revenue, 2020
      • 7.9.3 Baxter Healthcare Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Introduction
      • 7.9.4 Baxter Healthcare Response to COVID-19 and Related Developments
    • 7.10 Eisai
      • 7.10.1 Eisai Business Overview
      • 7.10.2 Eisai Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Production and Revenue, 2020
      • 7.10.3 Eisai Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Introduction
      • 7.10.4 Eisai Response to COVID-19 and Related Developments
    • 7.11 Especificos Stendhal
      • 7.11.1 Especificos Stendhal Business Overview
      • 7.11.2 Especificos Stendhal Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Production and Revenue, 2020
      • 7.11.3 Especificos Stendhal Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Introduction
      • 7.11.4 Especificos Stendhal Response to COVID-19 and Related Developments
    • 7.12 F.Hoffmann La Roche
      • 7.12.1 F.Hoffmann La Roche Business Overview
      • 7.12.2 F.Hoffmann La Roche Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Production and Revenue, 2020
      • 7.12.3 F.Hoffmann La Roche Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Introduction
      • 7.12.4 F.Hoffmann La Roche Response to COVID-19 and Related Developments
    • 7.13 Mundipharma
      • 7.13.1 Mundipharma Business Overview
      • 7.13.2 Mundipharma Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Production and Revenue, 2020
      • 7.13.3 Mundipharma Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Introduction
      • 7.13.4 Mundipharma Response to COVID-19 and Related Developments
    • 7.14 Mylan Pharmaceuticals
      • 7.14.1 Mylan Pharmaceuticals Business Overview
      • 7.14.2 Mylan Pharmaceuticals Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Production and Revenue, 2020
      • 7.14.3 Mylan Pharmaceuticals Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Introduction
      • 7.14.4 Mylan Pharmaceuticals Response to COVID-19 and Related Developments
    • 7.15 OPKO Health
      • 7.15.1 OPKO Health Business Overview
      • 7.15.2 OPKO Health Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Production and Revenue, 2020
      • 7.15.3 OPKO Health Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Introduction
      • 7.15.4 OPKO Health Response to COVID-19 and Related Developments
    • 7.16 Orchid Healthcare
      • 7.16.1 Orchid Healthcare Business Overview
      • 7.16.2 Orchid Healthcare Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Quarterly Production and Revenue, 2020
      • 7.16.3 Orchid Healthcare Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Introduction
      • 7.16.4 Orchid Healthcare Response to COVID-19 and Related Developments

    8 Supply Chain and Sales Channels Analysis

    • 8.1 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Supply Chain Analysis
      • 8.1.1 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Supply Chain Analysis
      • 8.1.2 Covid-19 Impact on Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Supply Chain
    • 8.2 Distribution Channels Analysis
      • 8.2.1 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Distribution Channels
      • 8.2.2 Covid-19 Impact on Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Distribution Channels
      • 8.2.3 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Distributors
    • 8.3 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Customers

    9 Key Findings

      10 Appendix

      • 10.1 About Us

      Summary:
      Get latest Market Research Reports on Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs. Industry analysis & Market Report on Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs is a syndicated market report, published as Global (United States, European Union and China) Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,250.00
      $4,875.00
      $6,500.00
      2,512.25
      3,768.38
      5,024.50
      3,025.75
      4,538.63
      6,051.50
      496,242.50
      744,363.75
      992,485.00
      274,300.00
      411,450.00
      548,600.00
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report